Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01941836 · ClinicalTrials.gov registry record · Phase 2

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

A Phase 2 study of Hypercholesterolemia, sponsored by Esperion Therapeutics.

Completed
Registry status
Phase 2
Development phase
349
Enrollment target
20
Study locations

NCT01941836: Completed Phase 2 study of Hypercholesterolemia, sponsored by Esperion Therapeutics.

NCT01941836 is a Phase 2 study of Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 349 participants, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01941836, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
349 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.

Conditions Studied

Hypercholesterolemia

Interventions

  • DRUG Ezetimibe
  • DRUG ETC-1002

Study Locations (20)

California

  • - Beverly Hills
  • - Chino
  • - Lincoln
  • - Long Beach
  • - Los Angeles
  • - Newport Beach
  • - Thousand Oaks
  • - Vista

Florida

  • - Atlantis
  • - Brandon
  • - Hialeah
  • - Jacksonville
  • - Oviedo
  • - Ponte Vedra
  • - Port Orange

Alabama

  • - Birmingham
  • - Muscle Shoals

Arizona

  • - Chandler

Colorado

  • - Denver

Connecticut

  • - Hartford

Trial Details

FieldValue
Enrollment Target 349 participants
Start Date 2013-09
Est. Completion 2014-11
Phase Phase 2
Esperion Therapeutics

23 total trials

What the finished NCT01941836 record still lists

NCT01941836 is an interventional study that assigns participants to a tested intervention. The registered 349 participants enrollment target is mid-sized for trials with a published cap, below the 811-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Ezetimibe is the first listed.

NCT01941836 names 20 study sites across 6 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT01941836 about?

NCT01941836 is a clinical study titled "Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients". The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevate...

What is the current status of trial NCT01941836?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2013-09. Estimated completion is 2014-11.

What conditions does trial NCT01941836 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT01941836?

The interventions under investigation include: Ezetimibe (DRUG), ETC-1002 (DRUG).

Who is sponsoring clinical trial NCT01941836?

This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01941836 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01941836's enrollment target sits among peer trials

349 24th of 62 higher than 39 of 62 other Hypercholesterolemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01941836, the US trial registry maintained by the National Library of Medicine. NCT01941836 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.